

Anavex Life Sciences | AVXL | Profile

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company's lead drug candidate for Alzheimer's Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Neurological diseases (CNS): Anavex SIGMACEPTOR™-N program involves the discovery and development of original drug candidates, targeting neurological diseases such as Alzheimer's disease, epilepsy, and depression. The company's lead drug

candidates exhibit high affinity and selectivity to sigma receptors and also synergistic action with other receptors, such as Muscarinic and NMDA, with strong evidence of anti-amnesic, neuroprotective, and anxiolytic properties.

Oncology: Anavex SIGMACEPTOR™-C program involves the discovery and development of original drug candidates targeting cancer. The company's lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells, without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as melanoma, prostate and pancreas, and neuropathic pain.

In addition, several series of sigma ligands currently at different stages of development, target stroke, diabetes, multiple sclerosis and Parkinson's disease.

The Pipe Line

Anavex's lead drug candidate ANAVEX 2-73 -targeting Alzheimer's Disease- is in Phase 1 clinical trials. The company has also initiated scale-up manufacturing of ANAVEX

1-41 targeting a range of important CNS disorders, including depression and Alzheimer's Disease. Three more of its compounds (for malignant melanoma, prostatic cancer and epilepsy) are expected to reach final preclinical stages in the near term.

Other early-stage preclinical research (see diagram) involves drug candidates that target diseases like depression, neuropathic pain and various types of cancer.

Source: [Anavex](#) , [OxBridge Research](#), [Daily Stock Deals](#)



Don't miss the NEXT premium Alert! Sign-up, Get Alerts, [MakeMoney](#)



we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.